Biomea Fusion, Inc. (BMEA) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Redwood City, CA, United States. वर्तमान CEO हैं Michael J. Hitchcock.
BMEA के पास है IPO तिथि 2021-04-16, 79 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $116.02M.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
